Pixium Vision

Report Publication Announcement • Jul 29, 2015

Pixium Vision announces the release of its 2015 Interim Financial Report

Paris, France. July 29th, 2015. 7:00 CET – Pixium Vision (FR0011950641 – PIX eligible to PEA-PME), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces today that it has released its 2015 interim financial report as at June 30th 2015. The report has been filed with the Autorité des marchés financiers in accordance with the regulated information guidelines.

The 2015 Interim Financial Report has been made available on the company's website, http://www.pixium-vision.com, in the section Financial Reports and Documents under the Investors tab.

Contacts

Pixium Vision Pierre Kemula, CFO investors@pixium-vision.com +33 1 76 21 47 30 @PixiumVision

Investor Relations Citigate Dewe Rogerson Lucie Larguier – Laurence Bault pixium-vision@citigate.fr +33 1 53 32 84 78

Press ex investors Newcap Media Annie-Florence Loyer – Nadège Le Lezec afloyer@newcap.fr nlelezec@newcap.fr

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision's VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. Pixium Vision plans to file IRIS's CE mark dossier before the end of 2015 and expects to launch IRIS® during the first half of 2016.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision is listed on Euronext (Compartment C) in Paris. ISIN: FR0011950641; Mnemo: PIX IRIS® is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forwardlooking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixiumvision.com).